Related Experiment Video
Updated: Aug 15, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
[Research Progresses in the Treatment of NSCLC with MET Gene Variants: A Riview]
Ran Chen1,2, Chang Jiang3, Jun Tang1
1Department of Oncology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China.
Abstract:
Mesenchymal-epithelial transition factor (MET) has long been considered as the most crucial and promising driver gene in the occurrence and development of non-small cell lung cancer (NSCLC), except for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and c-ROS oncogene 1 receptor tyrosine kinase (ROS1). In recent years, therapeutic drugs targeting MET have been continuously developed and applied in clinical practice. First, the curative effect of NSCLC patients with MET exon 14 skipping mutations has been further improved. In addition, when MET amplification occurs after resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in patients with advanced EGFR-mutant NSCLC, the combination of MET-TKIs and EGFR-TKIs has brought significant survival benefits and many other advances. This article reviews the treatment progress of NSCLC patients with different types of MET variants under different circumstances, which provides reference for the selection of clinical treatment strategies. .
Insights
Mesenchymal-epithelial transition factor (MET) targeting therapies significantly improve outcomes for non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations. Combination therapies offer survival benefits for advanced EGFR-mutant NSCLC with MET amplification.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Mesenchymal-epithelial transition factor (MET) is a key driver gene in non-small cell lung cancer (NSCLC) development, alongside EGFR, ALK, and ROS1.
- Recent advancements include the development and clinical application of targeted therapies against MET.
Approach:
- This review examines treatment progress for NSCLC patients with diverse MET variants.
- It analyzes therapeutic strategies in different clinical scenarios, including MET exon 14 skipping mutations and MET amplification post-EGFR tyrosine kinase inhibitor (TKI) resistance.
Key Points:
- Targeted MET therapies have improved curative effects for NSCLC patients with MET exon 14 skipping mutations.
- Combining MET-TKIs with EGFR-TKIs offers significant survival benefits for advanced EGFR-mutant NSCLC patients who develop MET amplification resistance.
- These advances provide valuable references for selecting clinical treatment strategies.
Conclusions:
- MET-targeted therapies represent a significant advancement in NSCLC treatment.
- Personalized treatment strategies based on specific MET alterations are crucial for improving patient outcomes.
- Further research into MET variants and combination therapies will continue to refine NSCLC management.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...